1. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. (4th May 2022) Authors: Deb, Arijita; Guggisberg, Patrik; Mutschler, Thomas; Owusu-Edusei, Kwame; Bencina, Goran; Johnson, Kelly D.; Ignacio, Tim; Mathijssen, Daan A.R.; Qendri, Venetia Journal: Expert review of vaccines Issue: Volume 21:Number 5(2022) Page Start: 711 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗